The proteasome is a large protease complex responsible for the degradation of key regulatory proteins involved in many cellular processes, including cell proliferation and survival. The observation that cancer cells are more sensitive to proteasome inhibition than normal cells has led to the development of several proteasome inhibitors for the treatment of cancer. The proteasome inhibitor bortezomib (the active ingredient of Velcade) is approved for the treatment of multiple myeloma and mantle cell lymphoma, while a number of second-generation proteasome inhibitors, which differ in their mode of inhibition and subunit specificity, are currently in clinical trials. With the proteasome emerging as a therapeutic target for cancer treatment, accurate tools for monitoring proteasome (inhibitor) activity are in demand. In this chapter, the synthesis and use of a fluorescent proteasome activity probe is described that allows for accurate profiling of proteasomal activity in cell lysates, intact cells and murine and patient material, with high sensitivity using SDS-PAGE. The probe allows for direct scanning of the gel for fluorescent emission of the distinct proteasomal subunits and circumvents the use of western-blot analysis. Due to its suitable biochemical and biophysical properties the fluorescent probe can also be used for confocal laser scanning microscopy and flow cytometry-based experiments.
Introduction
The use of proteasome inhibitors in the clinic for cancer treatment (1) , has validated the proteasome as therapeutic target. The proteasome is responsible for the degradation of misfolded and redundant proteins and of key regulatory proteins, involved in many cellular processes such as proliferation and survival (2, 3) . Inhibition of the proteasome causes disruption of many of these processes, eventually leading to cell death (1, 4) . The proteasome inhibitor bortezomib (1, 5) (Fig. 1 , the active compound of Velcade) is currently used for the treatment of multiple myeloma (6) and mantle cell lymphoma (7) .
A number of second-generation proteasome inhibitors, which differ in their mode of inhibition and subunit specificity, are currently in clinical trials.
Eukaryotic 26S proteasomes consist of a 20S core and one or two 19S regulatory caps.
The 19S regulatory caps are involved in the recognition and unfolding of polyubiquitinated substrates, while the catalytic activity takes place in the 20S core (3) .
The 20S proteasome is a barrel-shaped protein complex composed of four stacked rings that consist of seven subunits each. The two outer rings are made up of α-subunits and interact with the 19S regulatory caps. The two inner rings consist of β-subunits, from which three constitutive subunits, termed β1, β2 and β5, are responsible for proteolysis.
The β1, β2 and β5 subunits each provide a distinct protease activity, the caspase-like (cleavage after acidic residues), tryptic-like (cleavage after basic residues) and chymotryptic-like (cleavage after hydrophobic residues) activity, respectively. Upon interferon-γ stimulation, three additional immunoproteasome subunits are expressed (β1i, β2i and β5i), which replace the constitutive β1, β2 and β5 subunits to form the immunoproteasome. Immunoproteasomes are thought to have altered catalytic activity favoring production of antigenic peptides and are mainly expressed in lymphoid tissues, e.g. spleen, thymus and lymph nodes (8) .
Different cells can express different ratios of constitutive and immunoproteasome subunits (9, 10) . Variations in proteasomal composition affect substrate specificity and sensitivity to proteasome inhibition. To predict the sensitivity of patients to proteasome inhibitors, accurate tools are required that can correlate proteasome composition and the extent of proteasome inhibition to treatment response. As such, reagents that can be used to profile proteasome activity are valuable research tools and hold promise as diagnostic reagents.
Techniques that are commonly used to monitor proteasome activity include the application of fluorogenic substrates (11, 12) , small molecule-based activity assays (13) (14) (15) (16) (17) (18) and models based on recombinant reporter proteins (19) (20) (21) . Traditionally, fluorogenic substrates are used to measure the activity of the different proteasome active sites, but most fluorogenic substrates cannot be used in cells, and prior cell lysis is required before activity measurements can be performed. Reporter proteins can be used in living cells, but their use is limited to genetically altered cells or organisms. In addition, their activity readout depends on the balance between synthesis and degradation of fusion proteins, which involves many cellular factors other than the proteasome, including the rate of fusion-protein synthesis.
The first small molecule-based activity assay in its class that could be used to profile the specificity of proteasome inhibitors in living cells was reported in 2005 (13) . This dansylated vinylsulfone based proteasome probe ( Fig. 1) contains an α,β-unsaturated sulfone part that reacts through a Michael addition reaction with the γ-hydroxyl of the N-terminal threonine residue of catalytic β-subunits of the proteasome (22) , resulting in the formation of a β-sulfonyl ether linkage. Antibodies against the dansyl moiety were used for detection of labeled active subunits by SDS-PAGE and Western blot analysis (13) .
Subsequent replacement of the dansyl group by high quantum yield fluorophores allowed for direct scanning of the SDS-PAGE gel for fluorescence emission of fluorescently labeled subunits (14, 18) . Due to their favorable biochemical and biophysical properties Bodipy-based proteasome activity probes can be used to monitor proteasome activity in cell extracts, living cells and murine tissues using a range of techniques including SDS-PAGE (14) , confocal laser scanning microscopy (14, 18) and flow cytometry (14) .
Here, we describe the facile synthesis of the Bodipy-based fluorophore Me 4 BodipyFL-N-hydroxy-succinimidyl (NHS) ester from readily available starting materials in 6 steps. This fluorophore with an excitation maximum of 515 nm and an emission maximum of 519 nm can be detected using common fluorescein/GFP filter sets.
In addition, we describe the synthesis of the proteasome targeting moiety Ahx 3 Leu 3 VS and subsequent coupling with Me 4 BodipyFL-NHS ester yielding fluorescent probe Me 4 BodipyFL-Ahx 3 Leu 3 VS (Fig. 1) . Furthermore, optimized procedures are outlined for both SDS-PAGE and FACS based assays using this fluorescent probe.
Methods
In this section the synthesis of the fluorescent proteasome probe Me 4 BodipyFLAhx 3 Leu 3 VS (Fig. 1) is described as well as the use of this probe in SDS-PAGE and flow cytometry based experiments.
General Methods
1. L-Leucinyl vinyl sulfone was prepared as reported (22) (23) (24) (25) .
2. Flash column chromatography (26) refers to purification using the indicated eluent and Acros silica gel (0.030-0.075 mm).
3. Solution phase reactions were monitored using thin-layer chromatography (TLC) on silica coated plastic sheets (Merck silica gel F 254 ).
4. Nuclear magnetic resonance (NMR) spectra were recorded in the indicated solvent using a Bruker Avance 300 ( 1 H: 300 MHz; 13 C: 75 MHz) spectrometer.
5. LC-MS analyses were carried out on a WATERS LCT mass spectrometer in line with a WATERS 2795 HPLC system and a WATERS 2996 photodiode array detector.
Reversed phase runs were performed on a 3 µm Atlantis T3, C18 RP, 2.1 x 100 mm column (Waters) using gradient elution with H 2 O/0.1% formic acid as solvent A and acetonitrile/0.1% formic acid as solvent B at a flow rate of 0.4 mL/min.
6.
Reversed phase HPLC runs were performed on a Waters 1525 EF HPLC system in line with a Waters 2487 dual λ absorbance detector using gradient elution with H 2 O/0.05% TFA as solvent A and acetonitrile/0.05% TFA as solvent B. Analytical runs were performed on a 10 µm 4.6x150 mm Atlantis dC18 column (Waters) at a flow rate of 1.4
13 ml/min and preparative runs were performed on a 10 µm 19x250 mm Atlantis dC18 column (Waters) at a flow rate of 18 ml/min.
7.
Fluorescence spectra were measured on a customized fluorimeter set-up using a mercury vapor lamp at 72 W, appropriate gratings and a photomultiplier at 1000 V (Photon Technology International). Excitation spectra were recorded at 100 nM in water at 550 nm emission, while emission spectra were recorded in water at 480 nm excitation.
8. In-gel fluorescence intensity of SDS-PAGE gels was measured using a ProXPRESS 2D Proteomic imaging system (Perkin Elmer).
9. Flow cytometry experiments were performed using a FACSCalibur (BD Biosciences, 488 nm laser).
10. Cell lysates or samples containing protease activity were kept on ice until incubation with the probe.
11. Sonication of cells was performed on a Bioruptor.
Synthesis of the fluorescent proteasome probe Me 4 BodipyFL-

Ahx 3 Leu 3 VS
The Bodipy fluorescent dye described here was chosen for its ease of synthesis from commercially available reagents on a large scale and for its favorable spectral properties (fluorescein-like excitation and emission maxima), which make it widely applicable to common fluorescence based methodologies (e.g. fluorescence scanning, FACS The crude product can be used without further purification in the next step. 
Synthesis of Me 4 BodipyFL-Ahx 3 Leu 3 VS (see Note 3)
The synthesis of H 2 N-Ahx 3 Leu 2 -OH involving standard Fmoc-based solid-phase peptide synthesis (SPPS) protocols and the subsequent coupling of fluorescent dye and vinyl sulfone electrophile to yield the final proteasome probe are depicted in Scheme 2. in 40% yield (see Fig. 3 for LC/MS data). Fluorescence data: λ ex = 515 nm, λ em = 519.
Profiling of proteasome activity using SDS-PAGE based assays
Activity-based proteasome probes can be used to profile the effects of proteasome inhibitors in a broad range of sample types. Profiling experiments have been described in cell lysates and living cells (14) and ex vivo in both rodents (14) and patients (28). labeling of all three constitutive subunits (β1, β2, β5) in these cells (Fig. 4A) . THP-1 cells expressed both constitutive and immunoproteasome, as evidenced by the labeling of both the constitutive β2 and β5 proteasome subunits and the immunoproteasomal β2i and β1i subunits (Fig. 4B) . Incubation with different proteasome inhibitors resulted in the disappearance of particular bands on the gels, indicative of the subunit specificity of these inhibitors. Bortezomib inhibited only the β5(i) and β1(i) subunits, whereas both epoxomicin and MG132 inhibited all subunits. Epoxomicin completely inhibited the β2 and β2i and β1i subunits at 1 µM, while some residual activity of the β5/β5i subunits was still visible. On the other hand, 25 µM MG132 completely inhibited both the β5/β5i and β1/β1i activities but not the β2 and β2i subunits. These results are in accord with the published subunit specificities of these inhibitors. Bortezomib is a known inhibitor of the β5(i) and β1(i) activities, while both epoxomicin and MG132 are pan-proteasome inhibitors. A typical procedure is described below.
3.3.1
In vitro profiling of proteasome activity in cell lysates.
1. Grow the cell line of choice at 37º C and 5% CO 2 in a humidified incubator in the appropriate medium supplemented with 10% fetal calf serum (FCS) until log-phase (suspension cells) or until 80% confluency is reached (adherent cells). Medium may be supplemented with antibiotics. Include a reference sample to which 0.5 µL DMSO but no proteasome inhibitor is added.
Vortex and incubate the samples for the desired time period at 37 °C. 
Labeling of active proteasome subunits in living cells
Labeling of active proteasome subunits can be performed in suspension cells (proceed to step 1) or adherent cells (proceed to step 5).
Suspension cells
1. Grow the cell line of choice in appropriate medium containing 10% FCS at 37 ºC and 5% CO 2 in a humidified incubator until log phase is reached. Medium may be supplemented with antibiotics. 12. Centrifuge at 14,000 g for 3 minutes at 4°C to remove membrane fractions and cell debris. Transfer the supernatant to fresh eppendorf tube.
13. Determine protein concentrations using a Bradford assay. 
Gel electrophoresis and in-gel fluorescence readout
1. These instructions assume the use of the NuPAGE precast gel system (Invitrogen) and precast mini gels to separate proteins on SDS-PAGE. If a mini gel does not separate the individual proteasome subunits sufficiently, a larger gel system can be used, e.g. the PROTEAN II xi Cell system from Biorad (16x20 cm glass plates, 12.5% separating gel, 4% stacking gel.) When using this system, increase the sample volume to 50 µL per sample. Do not change the final concentrations of proteasome inhibitors, protein and probe in the samples. Load 20 to 30 µL sample per well and run at 10 mA for 16h.
Subsequently, increase the current to 35 mA, wait until the blue front has run off the gel and run for another hour before removing the gel from the system. The protocol described below can also be adapted to other gel systems. Use common protocols for denatured samples. Separate proteins using a 12 or 12.5% separating gel and a 4% stacking gel. Critical: when using the NuPAGE gel system also use the NuPAGE LDS sample buffer to prepare the 3X reducing sample buffer. The use of a different reducing sample buffer leads to improper running of the gel, resulting in fuzzy and unfocussed bands. 5. Remove the gel from the cassette and image the wet gel slab for 10 to 120s using a fluorescence imager containing an appropriate filter set (excitation at 480 nm, emission at 530 nm), e.g. the ProXPRESS 2D Proteomic imaging system (Perkin Elmer).
6. Analyze images using appropriate software (e.g. Totallab) to quantify fluorescence intensities.
Flow cytometry experiments
Fluorescent proteasome activity probes can be used to profile proteasome activity in cells using a fluorescence assisted cell sorting (FACS) assay. The advantage of this assay is that it can be used to measure both proteasome activation and proteasome inhibition in large numbers of samples. In this way, compounds can be screened for their effects on proteasome activity. Information on the activity of distinct subunits however is not obtained in flow cytometry based assays. Results of a typical FACS experiment are shown in Figure 6 . MelJuso cells (human melanoma) were incubated with 1 µM MG132, followed by incubation with probe (Fig. 5, blue curve) . As controls, cells were incubated with Me 4 BodipyFL-Ahx 3 Leu 3 VS only (Fig. 5, red curve) or not incubated (Fig. 5, black curve). Figure 5 shows a histogram in which the fluorescence intensity is plotted versus the cell count. In non-incubated cells, no fluorescence can be detected, resulting in a peak at low fluorescence intensity. When only probe is added, cells are fluorescently labeled, resulting in a shift of the cell population towards higher fluorescence intensity. Upon pre-incubation with MG132, the peak shifts back to lower fluorescence intensity. As some probe always aspecifically sticks to cell membranes, the signal in the MG132 treated population never returns to baseline values, although all proteasome is inhibited in these samples. Therefore, the signal intensity at 1 µM MG132 is taken as 100% inhibition, whereas the signal intensity in probe only-treated cells is taken as 0% inhibition. A typical procedure is described below. 
Notes
1. All buffers are prepared in water that has a resistivity of 18.2 MΩ-cm (MilliQ water).
2. Store stock solutions of ATP and DTT in water in aliquots at -20°C. Step numbers correspond to step numbers outlined in paragraph 3.2.1. 
